

Josuel Ora

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2335912/josuel-ora-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73
papers

1,674
citations

22
h-index

39
g-index

94
ext. papers

2,014
ext. citations

4.8
avg. IF

4.92
L-index

#	Paper	IF	Citations
73	The future of inhalation therapy in chronic obstructive pulmonary disease.. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022 , 3, 100092	3	1
72	Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. <i>Monaldi Archives for Chest Disease</i> , 2021 ,	2.7	1
71	New Avenues for Phosphodiesterase Inhibitors in Asthma. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 291-302	3	4
70	Sex differences in COPD management. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 323-332	3.8	3
69	Management of COPD patients during COVID: difficulties and experiences. <i>Expert Review of Respiratory Medicine</i> , 2021 , 15, 1025-1033	3.8	0
68	Step-up and step-down approaches in the treatment of asthma. <i>Expert Review of Respiratory Medicine</i> , 2021 , 15, 1159-1168	3.8	2
67	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. <i>Journal of Affective Disorders</i> , 2021 , 278, 339-340	6.6	4
66	Guidance on nebulization during the current COVID-19 pandemic. <i>Respiratory Medicine</i> , 2021 , 176, 1062366	3.6	19
65	Happy hypoxemia, or blunted ventilation?. <i>Respiratory Research</i> , 2021 , 22, 4	7.3	7
64	Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. <i>Expert Opinion on Drug Delivery</i> , 2021 , 18, 891-906	8	4
63	Treatable Mechanisms in Asthma. <i>Molecular Diagnosis and Therapy</i> , 2021 , 25, 111-121	4.5	5
62	Current long-acting muscarinic antagonists for the treatment of asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 2343-2357	4	0
61	Use of Thiols in the Treatment of COVID-19: Current Evidence. <i>Lung</i> , 2021 , 199, 335-343	2.9	2
60	Pulmonary Rehabilitation in Noncystic Fibrosis Bronchiectasis. <i>Respiration</i> , 2021 , 1-9	3.7	2
59	Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021 , 69, 102050	3.5	2
58	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. <i>Biologics: Targets and Therapy</i> , 2021 , 15, 363-374	4.4	2
57	SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	21

56	Does bronchoscopy help the diagnosis in COVID-19 infection?. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	18
55	As needed therapies in mild to severe asthma: a systematic review and network meta-analysis 2020 ,		2
54	Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease. <i>Journal of Experimental Pharmacology</i> , 2020 , 12, 559-574	3	6
53	Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits 2020 , 66-81		1
52	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. <i>Brain, Behavior, and Immunity</i> , 2020 , 88, 11-16	16.6	95
51	Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. <i>Neurological Sciences</i> , 2020 , 41, 2671-2674	3.5	4
50	Advances with glucocorticoids in the treatment of asthma: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 2305-2316	4	9
49	Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. <i>Multidisciplinary Respiratory Medicine</i> , 2019 , 14, 25	3	6
48	Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. <i>Molecular Diagnosis and Therapy</i> , 2019 , 23, 603-614	4.5	8
47	Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 737-750	4	12
46	Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. <i>Current Opinion in Pharmacology</i> , 2018 , 40, 34-38	5.1	16
45	Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018 , 49, 20-26	3.5	2
44	The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 589-596	4.1	8
43	An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. <i>Expert Review of Respiratory Medicine</i> , 2018 , 12, 43-54	3.8	8
42	Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. <i>BMC Pulmonary Medicine</i> , 2018 , 18, 70	3.5	32
41	Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 2043-2053	4	3
40	LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. <i>European Respiratory Review</i> , 2017 , 26,	9.8	43
39	Role of muscarinic antagonists in asthma therapy. <i>Expert Review of Respiratory Medicine</i> , 2017 , 11, 239-253	3.3	20

38	Optimizing drug delivery in COPD: The role of inhaler devices. <i>Respiratory Medicine</i> , 2017 , 124, 6-14	4.6	97
37	Indacaterol/Glycopyrronium Combination for COPD. <i>Pulmonary Therapy</i> , 2017 , 3, 45-57	3	2
36	Adherence to COPD treatment: Myth and reality. <i>Respiratory Medicine</i> , 2017 , 129, 117-123	4.6	37
35	Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017 , 44, 83-87	3.5	8
34	Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. <i>Respiratory Medicine</i> , 2017 , 129, 189-198	4.6	38
33	The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. <i>International Journal of COPD</i> , 2017 , 12, 3469-3485	3	27
32	Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016 , 4, 791-3	5.4	6
31	Onset of action of budesonide/formoterol Spiromax(□) compared with budesonide/formoterol Turbuhaler(□) in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016 , 39, 48-53	3.5	6
30	Gastroesophageal reflux and COPD exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link?. <i>Respirology</i> , 2016 , 21, 1496-1497	3.6	0
29	Dog allergen immunotherapy and allergy to furry animals. <i>Annals of Allergy, Asthma and Immunology</i> , 2016 , 116, 590	3.2	2
28	Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 977-88	4	8
27	Common Mechanisms of Dyspnea in Chronic Interstitial and Obstructive Lung Disorders. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 299-309	10.2	146
26	The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. <i>BioMed Research International</i> , 2016 , 2016, 4547953	3	8
25	Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. <i>Respiratory Research</i> , 2016 , 17, 70	7.3	58
24	Airflow obstruction: is it asthma or is it COPD?. <i>International Journal of COPD</i> , 2016 , 11, 3007-3013	3	33
23	Olodaterol for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 861-6	5.9	4
22	Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Clinical Pharmacology</i> , 2015 , 8, 529-39	3.8	10
21	Searching for the synergistic effect between acclidinium and formoterol: From bench to bedside. <i>Respiratory Medicine</i> , 2015 , 109, 1305-11	4.6	44

20	Pharmacological assessment of the onset of action of acclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. <i>European Journal of Pharmacology</i> , 2015 , 761, 383-90	5.3	28
19	Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. <i>COPD Research and Practice</i> , 2015 , 1,		22
18	Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol. <i>Therapeutics and Clinical Risk Management</i> , 2015 , 11, 1805-11	2.9	6
17	Canakinumab for the treatment of chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015 , 31, 15-27	3.5	47
16	Does exercise test modality influence dyspnoea perception in obese patients with COPD?. <i>European Respiratory Journal</i> , 2014 , 43, 1621-30	13.6	22
15	Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. <i>Respiratory Medicine</i> , 2014 , 108, 307-13	4.6	5
14	A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. <i>Respiratory Medicine</i> , 2013 , 107, 2014-21	4.6	9
13	Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. <i>Respiratory Medicine</i> , 2013 , 107, 107-11	4.6	8
12	Autonomic system modification in Zen practitioners. <i>Indian Journal of Medical Sciences</i> , 2013 , 67, 161-7		7
11	Effect of obesity on respiratory mechanics during rest and exercise in COPD. <i>Journal of Applied Physiology</i> , 2011 , 111, 10-9	3.7	57
10	Respiratory and leg muscles perceived exertion during exercise at altitude. <i>Respiratory Physiology and Neurobiology</i> , 2011 , 177, 162-8	2.8	18
9	Evolution of dyspnea during exercise in chronic obstructive pulmonary disease: impact of critical volume constraints. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 184, 1367-73	10.2	113
8	Effects of obesity on perceptual and mechanical responses to bronchoconstriction in asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 125-33	10.2	38
7	Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches. <i>Current Opinion in Pulmonary Medicine</i> , 2010 , 16, 144-9	3	17
6	Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. <i>Thorax</i> , 2009 , 64, 216-23	7.3	69
5	Bronchodilator effect on ventilatory, pulmonary gas exchange, and heart rate kinetics during high-intensity exercise in COPD. <i>European Journal of Applied Physiology</i> , 2009 , 107, 633-43	3.4	46
4	Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 964-71	10.2	96
3	Estimation of the exercise ventilatory compensation point by the analysis of the relationship between minute ventilation and heart rate. <i>European Journal of Applied Physiology</i> , 2008 , 104, 87-94	3.4	7

- 2 A case of pancytopenia and splenomegaly: haematological disease?. *Internal and Emergency Medicine*, **2007**, 2, 238-42 3-7
- 1 Long-Acting Muscarinic Antagonists in Asthma and COPD 268-295